Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVIS: BCG and Hepatitis B Immunisation at Birth
NCT02444611Completed
- Sponsor
- Murdoch Children's Research Institute
- Start
- Mar 2015
- Primary completion
- Jun 2016
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Randomised, open-label trial of bcg vaccine and Hepatitis B vaccine in Tuberculosis (TB) and hepatitis B (HBV) (4 arms), sponsored by Murdoch Children's Research Institute. Primary endpoint: Cytokine concentrations in response to in-vitro stimulation at 7 days. Started Mar 2015; status: completed.
02
Drugs
bcg vaccineHepatitis B vaccine
03
Conditions
Tuberculosis (TB)hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02444611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02444611.